Download Free Therapeutic Enzymes Function And Clinical Implications Book in PDF and EPUB Free Download. You can read online Therapeutic Enzymes Function And Clinical Implications and write the review.

Therapeutic enzymes exhibit fascinating features and opportunities, and represent a significant and promising subcategory of modern biopharmaceuticals for the treatment of several severe diseases. Research and drug developments efforts and the advancements in biotechnology over the past twenty years have greatly assisted the introduction of efficient and safe enzyme-based therapies for a range of both rare and common disorders. The introduction and regulatory approval of twenty different recombinant enzymes has enabled effective enzyme-replacement therapy. This volume aims to overview these therapeutic enzymes, focusing in particular on more recently approved enzymes produced by recombinant DNA technology. This volume is composed of four sections. Section 1 provides an overview of the production process and biochemical characterization of therapeutic enzymes, while Section 2 focuses upon the engineering strategies and delivery methods of therapeutic enzymes. Section 3 highlights the clinical applications of approved therapeutic enzymes, including aspects on their structure, indications and mechanisms of action. Together with information on these mechanisms, safety and immunogenicity issues and various adverse events of the recombinant enzymes used for therapy are discussed. Section 4, provides discussion on the prospective and future developments of new therapeutic enzymes. This book is aimed at academics, researchers and students undertaking advanced undergraduate/postgraduate programs in the biopharmaceutical/biotechnology area who wish to gain a comprehensive understanding of enzyme-based therapeutic molecules.
Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. - Highlights the potential of epigenetic alterations in cancer for drug development - Covers the tools and methods for epigenetic drug discovery, preclinical and clinical testing, and clinical implications of epigenetic therapy - Provides important information regarding putative epigenetic targets, epigenetic technologies, networks and consortia for epigenetic drug discovery and routes for translation
Biotechnology of Microbial Enzymes: Production, Biocatalysis, and Industrial Applications, Second Edition provides a complete survey of the latest innovations on microbial enzymes, highlighting biotechnological advances in their production and purification along with information on successful applications as biocatalysts in several chemical and industrial processes under mild and green conditions. The application of recombinant DNA technology within industrial fermentation and the production of enzymes over the last three decades have produced a host of useful chemical and biochemical substances. The power of these technologies results in novel transformations, better enzymes, a wide variety of applications, and the unprecedented development of biocatalysts through the ongoing integration of molecular biology methodology, all of which is covered insightfully and in-depth within the book. This fully revised, second edition is updated to address the latest research developments and applications in the field, from microbial enzymes recently applied in drug discovery to penicillin biosynthetic enzymes and penicillin acylase, xylose reductase, and microbial enzymes used in antitubercular drug design. Across the chapters, the use of microbial enzymes in sustainable development and production processes is fully considered, with recent successes and ongoing challenges highlighted. - Explores advances in microbial enzymes from basic science through application in multiple industry sectors - Includes up-to-date discussions of metabolic pathway engineering, metagenomic screening, microbial genomes, extremophiles, rational design, directed evolution, and more - Provides a holistic approach to the research of microbial enzymes and their use in sustainable processes and innovation - Features all new chapters discussing microbial enzyme classes of growing interest, as well as enzymes recently applied in drug discovery and other applications
This up-to-date reference book discusses the synthesis, production, and application of various microbial enzymes and metabolites for health. Microorganisms like bacteria (lactic acid bacteria, Bacillus species), yeasts, and filamentous fungi have been globally exploited for their biotechnological applications. This book discusses ways to use them commercially. Chapters include the production of fibrinolytic enzymes, microbial lipases, bacteriocin production by lactic acid bacteria, and bioactives produced. It also covers microbial synthesis of alkaloids, terpenoids, and steroids. This book is useful for researchers, academicians, and industry experts in microbiology and biotechnology.
Carbohydrate-Based Therapeutics Comprehensive resource summarizing opportunities and latest progress in design methodologies for carbohydrate-based therapeutics through a disease-oriented approach Carbohydrate-Based Therapeutics covers current progress and explores new frontiers in carbohydrate-based therapeutic applications, utilizing a unique approach by providing a detailed background of diseases coupled with subsequent carbohydrate-based therapies. The link between chemistry and design of novel carbohydrate-based medicines is highlighted and a broad overview of all the potential applications of carbohydrates is given. Emphasis is laid on concepts used for carbohydrate drug design, structure– activity relationship, and impact on health and diseases. The text also discusses newer topics like nanoparticles, material science, and tissue generation. Carbohydrate-Based Therapeutics includes information on: Antimicrobial carbohydrate-based therapies, covering antibacterial and antiviral vaccines, antifungal therapies, anti-influenza therapeutics, and antiadhesive carbohydrates and glycomimetics Anti-cancer carbohydrate-based therapies, covering cancer vaccines and immunotherapy, and carbohydrate tools in cancer biology Carbohydrate-based therapies in metabolic, neuronal, and immune disorders, covering carbohydrate-based therapeutics for lysosomal disorders and neurodegenerative diseases New frontiers in carbohydrate-based therapies, covering carbohydrates for tissue engineering, antiangiogenic and regenerative medicine Providing comprehensive coverage of foundational knowledge on the subject in a unique and highly accessible format while also exploring the state of the art in the field’s applications, Carbohydrate-Based Therapeutics is an essential resource for medicinal, pharmaceutical, and organic chemists, chemists in industry, biochemists, and biotechnologists.
Microbial species isolated from extreme and pristine habitats are always diverse, which indicates biomolecules secreted by these species might have importance. A cure for disease is a desire considering the catastrophic situations that threaten the lives of humans and animals. Currently, the world is facing the health, social and economic, and diplomatic impacts of infectious communicable diseases caused by bacteria and viruses. It is a necessity to understand the huge microbial diversity residing everywhere with us in this world. Microorganisms are species that were born at the start of “life” and will stay after the end of all other forms of life in this world. This unseen majority has significant effects on the biogeochemical cycle as well as has numerous medical and non-medical applications. So, the ability of microorganisms to produce bioactive compounds and how they can be used in different fields, especially medicine and health care, have been discussed in this book.
Green Sustainable Process for Chemical and Environmental Engineering and Science: Solvents for the Pharmaceutical Industry aims at providing a detailed overview of applications of green solvents in pharmaceutical industries. It also focuses on providing a detailed literature survey on the green solvents for pharmaceutical analysis, drug design, synthesis, and production, etc. It summarizes the applications of various greens solvents such as water, cyrene, vegetable oils, ionic liquids, ethyl lactate, eutectic solvents, and glycerol in contrast to toxic solvents. This book provides an overview of the use of green solvents for the sustainable and environmentally friendly development of synthetic methodologies for biomedical and pharmaceutical industries. - Up-to-date developments towards the development of solvents for pharmaceutical industry - Includes latest advances in pharmaceutical analysis and synthesis using green solvents - Outlines eco-friendly green solvents for medicinal applications - State-of-the-art overview on the exploration of green solvents for pharmaceutical industries
Germination of the thought of "Enzymatic- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges" Proceedings came about as part of the annual meeting of The American Association of Pharmaceutical Scientists (AAPS) that was held in San Diego in November of 2007. The attendance of workshop by more than 250 pharmaceutical scientists reflected the increased interest in the area of drug-drug interactions (DDIs), the greater focus of PhRMA, academia, and regulatory agencies, and the rapid pace of growth in knowledge. One of the aims of the workshop was to address the progress made in quantitatively predicting enzyme- and transporter-based DDIs as well as highlighted areas where such predictions are poor or areas that remain challenging for the future. Because of the serious clinical implications, initiatives have arisen from the FDA (http://www.fda.gov/cber/gdlns/interactstud.htm) to highlight the importance of enzyme- and transporter-based DDIs. During the past ten to fifteen years, we have come to realize that transporters, in addition to enzymes, play a vital role in drug elimination. Such insight has been possible because of the continued growth in PK-ADME (pharmacokinetics-absorption-distribution-metabolism-excretion) knowledge, fueled by further advances in molecular biology, greater availability of human tissues, and the development of additional and sophisticated model systems and sensitive assay methods for studying drug metabolism and transport in vitro and in vivo. This has sparked an in-depth probing into mechanisms surrounding DDIs, resulting from ligand-induced changes in nuclear receptors, as well as alterations in transporter and enzyme expression and function. Despite such advances, the in vitro and in vivo study of drug interactions and the integration of various data sets remain challenging. Therefore, it has become apparent that a proceeding that serves to encapsulate current strategies, approaches, methods and applications is necessary. As Editors, we have assembled a number of opinion leaders and asked them to contribute chapters surrounding these issues. Many of these are the original Workshop speakers whereas others had been selected specially to contribute on topics related to basic and applied information that had not been covered in other reference texts on DDI. The resulting tome, entitled Enzyme- and Transporter-Based Drug Interactions: Progress and Future Challenges, comprises of four sections. Twenty-eight chapters covering various topics and perspectives related to the subject of metabolic and transporter-based drug-drug interactions are presented.